Abstracts tagged "treatment"

Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
J. J. Gomez-Reino¹, A. Hazra², C. Fosser², S. Menon³, S. H. Zwillich², R. Riese² and S. Krishnaswami³, ¹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Pfizer Inc, Groton, CT, ³Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 1391 • 2013 ACR/ARHP Annual Meeting
Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis
Saliha Harrach¹, Christian Schmidt-Lauber², Bayram Edemir³, Eberhard Schlatter¹, Thomas Pap⁴, Giuliano Ciarimboli¹ and Jessica Bertrand², ¹Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Münster, Germany, ²Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, ³Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Muenster, Germany, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Tyrosine kinase inhibitors (TKI) are effective in treating malignant disorders and were suggested to also have an impact on non-malignant diseases such as rheumatoid…
Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Peter Dawes¹, Aleksandar Dimic², Mark C. Genovese³, Désiréé van der Heijde⁴, Martin Jenkins⁵, Chris O'Brien⁶, Barry Oemar⁷, Jiri Vencovsky⁸ and Michael Weinblatt⁹, ¹Department of Rheumatology, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, ²Rheumatology Institute, Niška Banja, Serbia, ³Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁶AstraZeneca R&D Wilmington, Wilmington, DE, ⁷AstraZeneca R&D Boston, Boston, MA, ⁸Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…
Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Thomas Stock¹, Dona Fleishaker², Xin Wang², Arnab Mukherjee² and Charles Mebus², ¹Pfizer Inc., Collegeville, PA, ²Pfizer Inc., Groton, CT
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Alan J. Kivitz¹, David McLain², John Hill³, Bruce Freundlich⁴, Jonathan Jaffe⁵ and Kaushik J. Dave⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Rheumatology, McLain Medical Associates, PC, Birmingham, AL, ³Avail Clinical Research, DeLand, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁶Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Mark Genovese¹, Désiréé van der Heijde², Edward Keystone³, Alberto Spindler⁴, Claude-Laurent Benhamou⁵, Arthur Kavanaugh⁶, Edward Fudman⁷, Kathy Lampl⁸, Chris O'Brien⁸, Emma Duffield⁹, Jeffrey Poiley¹⁰ and Michael Weinblatt¹¹, ¹Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³University of Toronto, Toronto, ON, Canada, ⁴Centro Medico Privado de Reumatologia, Tucuman, Argentina, ⁵Centre Hospitalier Régional d'Orléans, Orleans, France, ⁶University of California San Diego, San Diego, CA, ⁷Austin Rheumatology Research PA, Austin, TX, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁰Arthritis Associates, Orlando, FL, ¹¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…
Abstract Number: 2340 • 2013 ACR/ARHP Annual Meeting
Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶, Kenneth G. Saag⁷ and Jeffrey R. Curtis⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL
Title: Persistent Use of Biologic Therapies at Lower Than Recommended Dosing among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramBackground/Purpose: Biologic therapy is associated…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
MC Genovese¹, Joel M. Kremer², Ronald F. van Vollenhoven³, Rieke Alten⁴, Juan José Scali⁵, Ariella Kelman⁶, Lucy Rowell⁷ and Laura Pitts⁷, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany Medical College, Albany, NY, ³Karolinska Institute, Stockholm, Sweden, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵Durand University Hospital, Buenos Aires, Argentina, ⁶Genentech, South San Francisco, CA, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting
Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers
Victoria L. Ruffing¹ and Kaushik J. Dave², ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting
Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis
Ichiro Miki¹ and Masako Uchii², ¹Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, ²Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan
Background/Purpose: Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.